When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001). Weight loss ...
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback